(MedPage Today) — The vast majority of patients with stage III resectable melanoma treated with neoadjuvant and adjuvant dual immunotherapy — nivolumab (Opdivo) and relatlimab (Opdualag) — remained alive and disease-free after almost 4 years…
Source link : https://www.medpagetoday.com/oncology/skincancer/116494
Author :
Publish date : 2025-07-14 18:45:00
Copyright for syndicated content belongs to the linked Source.
